Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

There is emerging evidence that the balance between estrogen receptor-alpha (ER(alpha)) and androgen receptor (AR) signaling is a critical determinant of growth in the normal and malignant breast. In this study, we assessed AR status in a cohort of 215 invasive ductal breast carcinomas. AR and (ER(alpha)) were coexpressed in the majority (80-90%) of breast tumor cells. Kaplan-Meier product limit analysis and multivariate Cox regression showed that AR is an independent prognostic factor in (ER(alpha))-positive disease, with a low level of AR (less than median of 75% positive cells) conferring a 4.6-fold increased risk of cancer-related death (P = 0.002). Consistent with a role for AR in breast cancer outcome, AR potently inhibited (ER(alpha))transactivation activity and 17beta-estradiol-stimulated growth of breast cancer cells. Transfection of MDA-MB-231 breast cancer cells with either functionally impaired AR variants or the DNA-binding domain of the AR indicated that the latter is both necessary and sufficient for inhibition of (ER(alpha)) signaling. Consistent with molecular modeling, electrophoretic mobility shift assays showed binding of the AR to an estrogen-responsive element (ERE). Evidence for a functional interaction of the AR with an ERE in vivo was provided by chromatin immunoprecipitation data, revealing recruitment of the AR to the progesterone receptor promoter in T-47D breast cancer cells. We conclude that, by binding to a subset of EREs, the AR can prevent activation of target genes that mediate the stimulatory effects of 17beta-estradiol on breast cancer cells.

[1]  Heike Brand,et al.  Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.

[2]  D. Pfaff,et al.  Interactions of estrogen- and thyroid hormone receptors on a progesterone receptor estrogen response element (ERE) sequence: a comparison with the vitellogenin A2 consensus ERE. , 1997, Molecular endocrinology.

[3]  B. Edwards,et al.  Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.

[4]  E. Wilson,et al.  Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. , 1999, Molecular endocrinology.

[5]  C. P. Morris,et al.  PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.

[6]  G. Lyman,et al.  Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. , 2008, Human pathology.

[7]  V. Jordan,et al.  Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer , 2007, Steroids.

[8]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[9]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[10]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[11]  S. Andò,et al.  Endogenous Coactivator ARA70 Interacts with Estrogen Receptor α (ERα) and Modulates the Functional ERα/Androgen Receptor Interplay in MCF-7 Cells* , 2005, Journal of Biological Chemistry.

[12]  A. Bilancio,et al.  Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. , 2005, Cancer research.

[13]  S. Marzouk,et al.  The plasticity of estrogen receptor–DNA complexes: Binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  Hao Li,et al.  Cell- and gene-specific regulation of primary target genes by the androgen receptor. , 2007, Genes & development.

[15]  B. Anderson,et al.  Androgens and androgen receptors: A clinically neglected sector in breast cancer biology , 2007, Journal of surgical oncology.

[16]  John W. R. Schwabe,et al.  The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements , 1993, Cell.

[17]  J. Schwabe.  Transcriptional control: How nuclear receptors get turned on , 1996, Current Biology.

[18]  G. Buchanan,et al.  Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  R. Lanz,et al.  Nuclear receptor coregulators and human disease. , 2008, Endocrine reviews.

[20]  J. A. Kemppainen,et al.  FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor* , 2000, The Journal of Biological Chemistry.

[21]  D. Horsfall,et al.  Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. , 2005, Cancer research.

[22]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[23]  E. Simpson.  Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  J. Visvader,et al.  Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Coetzee,et al.  Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity , 2008, PloS one.

[26]  B. Katzenellenbogen,et al.  Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Coetzee,et al.  Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. , 2003, Molecular cancer research : MCR.

[28]  R. Kraus,et al.  Estrogen-related receptor alpha 1 functionally binds as a monomer to extended half-site sequences including ones contained within estrogen-response elements. , 1997, Molecular endocrinology.

[29]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[30]  Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.

[31]  D. Schaid,et al.  Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis , 1991, Cancer.

[32]  G. Coetzee,et al.  Structural and functional consequences of glutamine tract variation in the androgen receptor. , 2004, Human molecular genetics.

[33]  S. Andò,et al.  Breast cancer: from estrogen to androgen receptor , 2002, Molecular and Cellular Endocrinology.

[34]  D. Horsfall,et al.  Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Wilson,et al.  Characterization and expression of a cDNA encoding the human androgen receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Claessens,et al.  DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation. , 2003, The Biochemical journal.

[37]  Zhiyong Guo,et al.  Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. , 2006, Cancer research.

[38]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[39]  L. Pinsky,et al.  Interactions between androgen and estrogen receptors and the effects on their transactivational properties , 2000, Molecular and Cellular Endocrinology.

[40]  K. Wernecke,et al.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer , 2006, Virchows Archiv.

[41]  M. Brown,et al.  Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. , 2006, Molecular endocrinology.

[42]  C. Geserick,et al.  New androgen response elements in the murine pem promoter mediate selective transactivation. , 2001, Molecular endocrinology.

[43]  F. Claessens,et al.  Structural basis of androgen receptor binding to selective androgen response elements. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Yeh,et al.  Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor , 2003, The Journal of experimental medicine.

[45]  Gert Vriend,et al.  Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field , 2002, Proteins.

[46]  Frank Claessens,et al.  Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. , 2003, Molecular genetics and metabolism.

[47]  S. Catalano,et al.  Estrogen Receptor α Binds to Peroxisome Proliferator–Activated Receptor Response Element and Negatively Interferes with Peroxisome Proliferator–Activated Receptor γ Signaling in Breast Cancer Cells , 2005, Clinical Cancer Research.

[48]  Paul E Swanson,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.

[49]  D. Horsfall,et al.  Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non‐organ confined disease , 2005, The Prostate.

[50]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[51]  T. Brown,et al.  Identification and Characterization of a Novel Androgen Response Element Composed of a Direct Repeat* , 1997, The Journal of Biological Chemistry.